MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Steven Chaouki Purchases 40,849 Shares of Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Steven Chaouki purchased 40,849 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was bought at an average cost of $1.22 per share, for a total transaction of $49,835.78. Following the completion of the purchase, the director directly owned 151,873 shares in the company, valued at approximately $185,285.06. This trade represents a 36.79% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

MAIA Biotechnology Price Performance

NYSEAMERICAN MAIA opened at $1.36 on Wednesday. The business’s 50-day moving average is $1.21 and its 200 day moving average is $1.50. The stock has a market capitalization of $50.36 million and a PE ratio of -1.86. MAIA Biotechnology, Inc. has a 1 year low of $0.87 and a 1 year high of $2.74.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its earnings results on Friday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.08). As a group, equities research analysts anticipate that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current year.

Institutional Investors Weigh In On MAIA Biotechnology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Centric Wealth Management grew its stake in shares of MAIA Biotechnology by 740.2% in the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock worth $1,032,000 after buying an additional 505,150 shares during the last quarter. Geode Capital Management LLC lifted its stake in MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after acquiring an additional 7,746 shares during the period. Jane Street Group LLC bought a new position in MAIA Biotechnology during the second quarter valued at approximately $52,000. Centerpoint Advisory Group purchased a new position in shares of MAIA Biotechnology in the 2nd quarter worth $28,000. Finally, Marshall Wace LLP purchased a new position in MAIA Biotechnology in the second quarter worth about $29,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.